Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
VYGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.75 - $9.55
Previous CloseN/A
Volume91.62K
Average Volume (3M)404.74K
Market Cap
$165.07M
Enterprise Value$105.76M
Total Cash (Recent Filing)-$135.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)5.0
Beta1.19
Next Earnings
May 13, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding55,206,886
10 Day Avg. Volume494,523
30 Day Avg. Volume404,742
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.68
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.32
Enterprise Value/Ebitda-1.35
Forecast
1Y Price Target
$15.13Price Target Upside377.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Voyager Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe anti-tau antibody VY7523 demonstrated good safety and tolerability in a study with 48 healthy volunteers, showing dose-dependent pharmacokinetics and sufficient CNS penetration.
Financial HealthVoyager Therapeutics remains well-capitalized, with a cash runway into mid-2027, and its strategic partnerships provide additional potential milestone payments of up to $8.2 billion.
Research And DevelopmentCompelling updates on Alzheimer's programs with new preclinical data from anti-tau antibody VY7523 and tau silencing gene therapy VY1706 strengthen the case for Voyager's dual approach to tau-targeted therapy.
Bears Say
Financial PerformanceFY24 total revenue of $80mm was below consensus expectations.
Research And Development CostsR&D of $127.4mm was above consensus expectations, indicating higher than expected research and development expenses.
Uncertainty In Treatment OutcomesVYGR noted there is currently no consensus on how APOε4 status may affect patients' response to treatment, indicating uncertainty in treatment outcomes.
---
Ownership Overview
2.73% Insiders
12.80% Mutual Funds
29.88% Other Institutional Investors
44.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $2.75 and its highest was $9.55 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $165.07M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 29 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Mar 11, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.223.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 55,206,886 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went up 2.267%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
---
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.13 (377.29% Upside)
$15.13 (377.29% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 278.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $248.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.89%
12-Months-Change
Fundamentals
Return on Equity
-24.25%
Trailing 12-Months
Asset Growth
11.89%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
---
VYGR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.Read More>---
VYGR Stock 12 Month Forecast
Average Price Target
$15.13
▲(377.29% Upside)
Technical Analysis
Annexon Biosciences
―
Foghorn Therapeutics
―
4D Molecular Therapeutics
―
Terns Pharmaceuticals
―
Prime Medicine, Inc.
―
Best Analysts Covering VYGR
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
-6.88%
reiterated a buy rating 5 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of -6.88% per trade.
---